ANTIHYPERTENSIVE DRUGS MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-90139 | Health Care
Historical data: 2017 - 2023
Forecast period: 2025 - 2031
Quantitative units: Revenue in USD million and CAGR from 2025 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Antihypertensive Drugs Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL ANTIHYPERTENSIVE DRUGS MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL ANTIHYPERTENSIVE DRUGS MARKET
7.1 GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE (2017 - 2031) (USD MILLION)
8.1 GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
8.2 GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
9.1 GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
9.2 GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
10.1 GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY REGION (2017 - 2023) (USD MILLION)
10.2 GLOBAL ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY REGION (2025 - 2031) (USD MILLION)
11.1 NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
11.2 NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
11.3 NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
11.4 NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
11.5 NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
11.6 NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
12.1 EUROPE ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
12.2 EUROPE ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
12.3 EUROPE ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
12.4 EUROPE ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
12.5 EUROPE ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
12.6 EUROPE ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
13.1 ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
13.2 ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
13.3 ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
13.4 ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
13.5 ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
13.6 ASIA PACIFIC ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
14.1 LATIN AMERICA ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)/p>
14.2 LATIN AMERICA ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
14.3 LATIN AMERICA ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
14.4 LATIN AMERICA ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
14.5 LATIN AMERICA ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
14.6 LATIN AMERICA ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY COUNTRY (2017 - 2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY COUNTRY (2025 - 2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY TYPE (2017 - 2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY TYPE (2025 - 2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2017 - 2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA ANTIHYPERTENSIVE DRUGS MARKET SIZE AND SHARE BY APPLICATION (2025 - 2031)< (USD MILLION)/p>
16.1 Novartis International AG (Switzerland)
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Pfizer Inc. (United States)
16.3 Johnson & Johnson (United States)
16.4 Sanofi S.A (France)
16.5 Lupin Limited (India)
16.6 Ranbaxy Laboratories (India)
16.7 Merck & Co. (United States)
16.8 AstraZeneca plc (United Kingdom)
16.9 Daiichi Sankyo Company (Japan)
16.10 Takeda Pharmaceutical Company (Japan)
16.11 Actelion (Switzerland)
16.12 United Therapeutics Corporation (United States)
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By Disease TypePrimary Hypertension
Secondary Hypertension
By End-users
Hospitals
Clinics
Others
By Distribution Channel
Retail Pharmacy
Hospital Pharmacy
E-commerce Websites & Online Drug Stores
Others
By Therapeutic Class
Calcium Channel Blockers
Beta-adrenergic Blockers
Renin Inhibitors
ACE Inhibitors
Vasodilators
Diuretics
ARBs
Others
Companies
Novartis International AG (Switzerland)
Pfizer Inc. (United States)
Johnson & Johnson (United States)
Sanofi S.A (France)
Lupin Limited (India)
Ranbaxy Laboratories (India)
Merck & Co. (United States)
AstraZeneca plc (United Kingdom)
Daiichi Sankyo Company (Japan)
Takeda Pharmaceutical Company (Japan)
Actelion (Switzerland)
United Therapeutics Corporation (United States)
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.